Pushing the boundaries of science and medical engineering for the improvement of health: Ultimaster combines an optimal balance between stent design for ultimate conformability with simultaneous polymer resorption and drug release, to match the procedure-triggered biological response in the vessel.1 This results in optimal vessel recovery and potentially shortened DAPT time.2Mastering rapid and healthy coronary vascular repair.
No drug polymer coating on parts of the stent that experience the most physical stress.5
Open cell, 2-link design for easy side-branch access
Uniform architecture for optimal coverage of bifurcation anatomy
Gradient coating ensures polymer integrity reducing risk of delamination, even when overexpanded3
Side branch expansion
Test method: Expand a cell with a balloon at nominal pressure
Cell area: 14.5 mm²
One of the largest, prospective worldwide registries
60 MVD patients with OFDI, single arm, primary endpoint TLF @ 12M. Published
Recommended DES in ESC/EACTS 2014 guidelines.6
1 month DAPT. CE Mark approved for patients in need.2
1 Data on file at Terumo Corporation (Doc nr. BioRes02-T).2 Ultimaster IFU. 1 month DAPT CE Mark approved for patients in need. Patients should be maintained on clinically adequate post-procedural antiplatelet therapy according to the current guidelines. In case of need, dual antiplatelet therapy can be discontinued earlier, but not before one month.3 Comparing to DES with uniform coating. Saito N. et al. Drug diffusion and biological responses of arteries using a drug-eluting stent with nonuniform coating. Medical Devices: Evidence and Research 2016:9.4 Virmani R. CvPath Rabbit Iliac artery. Barbato E. Presented at EuroPCR 2013.5 Data on file at Terumo Corporation (Doc nr. Grad01-T).6 Orvin K et al. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial. Catheter Cardiovasc Inter v. 2015 Aug 13. doi: 10.1002/ccd.26150.7 Windecker S et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619.
Our sales representatives are here for you.
Thank you for contacting us!
We typically respond within 2 business days and will come back to you as soon as possible.
Radifocus™ Introducer II Radiopaque Marker Kit C
Radifocus™ Torque Device
Radifocus™ Haemostasis Valve
Radifocus™ Guide Wire M Standard Type
Radifocus™ Guide Wire M Stiff Type
Didn't find your product?
This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public
For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.